Oncology Early Phase / Multiple Disease Site Hematologic Malignancies Early Phase Team Plasma Cell Disorders Multiple Myeloma Relapsed/Refractory 3 or more prior lines
Categories
Protocols
ABBVIE-M22-947 Phase I OPEN TO ACCRUAL
A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma